REMS In The Time Of COVID-19: ACLU Sues FDA Over Abortion Pill Access
Executive Summary
Medical and advocacy groups claim FDA is requiring women to fill prescriptions for Mifeprex in person while waiving REMS requirement for in-person visits for other drugs.
You may also be interested in...
Mifepristone Access Imperiled By Supreme Court’s Draft Decision Overturning Abortion Rights
Clinicians in states that ban abortion could face criminal prosecution for providing mifepristone. Access to medical abortion ‘is not a panacea’ if the court overrules Roe v. Wade as people using the drug face risks from aggressive prosecutors, ACLU attorney says.
Abortion Pill Mifepristone Will No Longer Require In-Person Pick Up, US FDA Concludes
REMS modification implemented for the duration of the pandemic will become permanent, the agency determines in response to lawsuit. FDA adds a requirement that pharmacies dispensing the drug be certified.
Opioids, Abortion, And Drug Advertising: How A Califf-Led FDA Might Address Hot Button Rx Topics
Robert Califf offers some interesting clues as to how he’d handle top drug policy issues in his Senate confirmation hearing.